The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...

A tumor-informed ctDNA assay identified MRD in TNBC patients, indicating a 30-fold higher risk of distant recurrence for MRD-positive individuals. The NSABP B-59/GBG 96-GeparDouze trial involved 1550 ...

Alpelisib plus fulvestrant significantly improved PFS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, achieving a median PFS of 7.4 months versus 2.8 months with placebo. The ...

More recently, the FDA posted two two letters: one backdated for September 9, regarding GSK’s HIV medication Apretude and one backdated for November 24 for Daiichi Sankyo’s tenosynovial giant cell ...

Sacituzumab govitecan failed to extend PFS in patients with hormone receptor-positive, HER2-negative breast cancer following ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Previous findings from the phase 3 DESTINY-Breast05 study (NCT04622319) showed that T-DXd demonstrated statistically significant and clinically meaningful improvement vs T-DM1 in the primary endpoint ...

SAN ANTONIO – Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic ...

Leading breast cancer nonprofits Unite for HER and TOUCH, The Black Breast Cancer Alliance (TOUCHBBCA) presented new and ...

The addition of tucatinib to first-line trastuzumab plus pertuzumab delayed disease progression among a cohort of women with ...

AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. | Pfizer has rolled out detailed trial ...